Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Q-Line Biotech's Enterprise Value is ₹15,174 Mil.
Q-Line Biotech does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Q-Line Biotech's EV-to-EBIT at this moment.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Q-Line Biotech's Enterprise Value is ₹15,174 Mil.
Q-Line Biotech does not have enough years/quarters to calculate its EBITDA for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Q-Line Biotech's EV-to-EBITDA at this moment.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Q-Line Biotech's Enterprise Value is ₹15,174 Mil.
Q-Line Biotech does not have enough years/quarters to calculate its Revenue for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Q-Line Biotech's EV-to-Revenue at this moment.
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Q-Line Biotech's Enterprise Value is ₹15,174 Mil.
Q-Line Biotech does not have enough years/quarters to calculate its Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025. Therefore, GuruFocus does not calculate Q-Line Biotech's EV-to-FCF at this moment.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Q-Line Biotech (NSE:QLINE) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
Q-Line Biotech Enterprise Value Related Terms
Q-Line Biotech Enterprise Value Historical Data
* Premium members only.
The historical data trend for Q-Line Biotech's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech Enterprise Value Chart
Q-Line Biotech Annual Data
Trend
Mar23
Mar24
Mar25
Enterprise Value
0.00
0.00
0.00
Q-Line Biotech Semi-Annual Data
Mar23
Mar24
Mar25
Enterprise Value
0.00
0.00
0.00
NSE:QLINE vs ABT, SYK, MDT: Enterprise Value Comparison
For the Medical Devices subindustry, Q-Line Biotech's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Q-Line Biotech Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Q-Line Biotech's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Q-Line Biotech's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Q-Line Biotech's Enterprise Value for the fiscal year that ended in Mar. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Q-Line Biotech (NSE:QLINE) has a Enterprise Value of ₹15,174 Mil as of Jun. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Q-Line Biotech and its competitors.
Is Q-Line Biotech's Enterprise Value too high?
Q-Line Biotech's current Enterprise Value is ₹15,174 Mil. Overall, Q-Line Biotech has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Q-Line Biotech's Enterprise Value compare to ABT and SYK?
Q-Line Biotech's Enterprise Value of ₹15,174 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Q-Line Biotech and its competitors. Q-Line Biotech's current Enterprise Value is ₹15,174 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Q-Line Biotech stock overvalued right now?
Q-Line Biotech (NSE:QLINE) has a current Enterprise Value of ₹15,174 Mil. The current Enterprise Value is ₹15,174 Mil. Q-Line Biotech's overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Q-Line Biotech (NSE:QLINE), the current Enterprise Value is ₹15,174 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Q-Line Biotech Ltd is engaged in the business of developing, manufacturing and marketing of diverse range of reagents (including kits and POC devices) & consumables and manufacturing, importing, distribution/supply of diagnostic equipment for different diagnostic healthcare needs. The company supplies diagnostic equipment and IVD products for different diagnostic healthcare needs directly or through its distributors majorly to diagnostic service providers, hospitals and medical colleges. It is engaged in Manufacturing and Trading into Biochemistry Regnant, Instruments and Consumables. The majority of revenue is derived from the Manufacturing segment.
12GF Score
Get the complete analysis for NSE:QLINE
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:QLINE has been successfully added to your 